GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Roivant Sciences Ltd (NAS:ROIV) » Definitions » Beneish M-Score

Roivant Sciences (Roivant Sciences) Beneish M-Score : -1.10 (As of Apr. 25, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Roivant Sciences Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Warning Sign:

Beneish M-Score -1.1 higher than -1.78, which implies that the company might have manipulated its financial results.

The historical rank and industry rank for Roivant Sciences's Beneish M-Score or its related term are showing as below:

ROIV' s Beneish M-Score Range Over the Past 10 Years
Min: -3.69   Med: -1.41   Max: 0.79
Current: -1.1

During the past 3 years, the highest Beneish M-Score of Roivant Sciences was 0.79. The lowest was -3.69. And the median was -1.41.


Roivant Sciences Beneish M-Score Historical Data

The historical data trend for Roivant Sciences's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Roivant Sciences Beneish M-Score Chart

Roivant Sciences Annual Data
Trend Mar21 Mar22 Mar23
Beneish M-Score
- - 0.79

Roivant Sciences Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.94 0.79 -1.88 -1.41 -1.10

Competitive Comparison of Roivant Sciences's Beneish M-Score

For the Biotechnology subindustry, Roivant Sciences's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Roivant Sciences's Beneish M-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Roivant Sciences's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Roivant Sciences's Beneish M-Score falls into.



Roivant Sciences Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Roivant Sciences for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.7507+0.528 * 0.8928+0.404 * 0.2834+0.892 * 2.8576+0.115 * 0.4949
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.3667+4.679 * 0.00405-0.327 * 0.3106
=-1.10

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Total Receivables was $63.2 Mil.
Revenue was 37.14 + 37.101 + 21.624 + 27.376 = $123.2 Mil.
Gross Profit was 33.472 + 33.835 + 17.41 + 23.201 = $107.9 Mil.
Total Current Assets was $6,806.7 Mil.
Total Assets was $7,312.7 Mil.
Property, Plant and Equipment(Net PPE) was $68.8 Mil.
Depreciation, Depletion and Amortization(DDA) was $22.8 Mil.
Selling, General, & Admin. Expense(SGA) was $643.3 Mil.
Total Current Liabilities was $244.9 Mil.
Long-Term Debt & Capital Lease Obligation was $450.4 Mil.
Net Income was 5096.184 + -304.327 + -291.816 + -33.617 = $4,466.4 Mil.
Non Operating Income was 5363.355 + -69.909 + -69.983 + 49.241 = $5,272.7 Mil.
Cash Flow from Operations was -210.452 + -196.427 + -249.932 + -179.088 = $-835.9 Mil.
Total Receivables was $29.5 Mil.
Revenue was 17.052 + 12.533 + 4.319 + 9.223 = $43.1 Mil.
Gross Profit was 13.466 + 8.892 + 2.593 + 8.764 = $33.7 Mil.
Total Current Assets was $1,646.2 Mil.
Total Assets was $2,203.0 Mil.
Property, Plant and Equipment(Net PPE) was $91.9 Mil.
Depreciation, Depletion and Amortization(DDA) was $12.9 Mil.
Selling, General, & Admin. Expense(SGA) was $614.0 Mil.
Total Current Liabilities was $244.3 Mil.
Long-Term Debt & Capital Lease Obligation was $430.0 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(63.188 / 123.241) / (29.454 / 43.127)
=0.512719 / 0.68296
=0.7507

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(33.715 / 43.127) / (107.918 / 123.241)
=0.781761 / 0.875666
=0.8928

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (6806.733 + 68.755) / 7312.679) / (1 - (1646.232 + 91.931) / 2202.96)
=0.059785 / 0.210987
=0.2834

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=123.241 / 43.127
=2.8576

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(12.904 / (12.904 + 91.931)) / (22.764 / (22.764 + 68.755))
=0.123089 / 0.248735
=0.4949

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(643.337 / 123.241) / (613.969 / 43.127)
=5.220154 / 14.236302
=0.3667

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((450.396 + 244.899) / 7312.679) / ((430.049 + 244.255) / 2202.96)
=0.095081 / 0.30609
=0.3106

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(4466.424 - 5272.704 - -835.899) / 7312.679
=0.00405

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Roivant Sciences has a M-score of -1.10 signals that the company is likely to be a manipulator.


Roivant Sciences Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Roivant Sciences's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Roivant Sciences (Roivant Sciences) Business Description

Traded in Other Exchanges
Address
50 Broadway, 7th Floor, London, GBR, SW1H 0BD
Roivant Sciences Ltd is a biopharmaceutical company dedicated to improving the delivery of healthcare to patients.
Executives
Eric Venker officer: President & COO C/O ROIVANT SCIENCES, INC., 320 WEST 37TH STREET, 6TH FLOOR, NEW YORK NY 10018
Keith S Manchester director C/O ROIVANT SCIENCES LTD., 11-12 ST. JAMES'S SQUARE SUITE 1, 3RD FL, LONDON X0 SW1Y 4L
Daniel Allen Gold director 6720 VIA AUSTI PARKWAY, SUITE 450, LAS VEGAS NV 89119
Qvt Financial Lp 10 percent owner, other: Director by Deputization 888 SEVENTH AVENUE, 43RD FLOOR, NEW YORK NY 10106
Svf Investments (uk) Ltd 10 percent owner 69 GROSVENOR STREET, LONDON X0 W1K3JP
Rakhi Kumar officer: Chief Accounting Officer C/O NEUROPACE INC, 455 N BERNARDO AVENUE, MOUNTAIN VIEW CA 94043
Viking Global Investors Lp 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Viking Global Performance Llc 10 percent owner 55 RAILROAD AVENUE, 3RD FLOOR, GREENWICH CT 06830
Sumitomo Chemical Co., Ltd. 10 percent owner 7-1, NIHONBASHI 2-CHOME, CHUO-KU, TOKYO M0 103-6020
Viking Global Opportunities Parent Gp Llc 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Softbank Vision Fund L.p. 10 percent owner AZTEC GROUP HOUSE, 11-15 SEATON PLACE, ST HELIER Y9 JE4 0QH
Meghan Fitzgerald director C/O VION PHARMACEUTICALS, INC., 4 SCIENCE PARK, NEW HAVEN CT 06511
Richard Pulik officer: CFO SUITE 1, 3RD FLOOR, 11-12 ST. JAMES'S SQUARE, LONDON X0 SW1Y 4LB
Vivek Ramaswamy director C/O ONCORE BIOPHARMA, INC., 3805 OLD EASTON ROAD, DOYLESTOWN PA 18902
Dexcel Pharma Technologies Ltd. 10 percent owner 1 DEXCEL STREET, OR AKIVA L3 3060000

Roivant Sciences (Roivant Sciences) Headlines

From GuruFocus

QVT Financial LP Reduces Stake in Roivant Sciences Ltd

By GuruFocus Research 10-03-2023